RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate. A 24-week, Prospective, Open-label, Multicenter Trial Evaluating Treatment Satisfaction in Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment Change From Tecfidera™ to Rebif® 44 mcg Subcutaneously (sc) Three Times Weekly (Tiw)

This is a Phase IV, prospective, open-label, multi-center trial to assess the treatment satisfaction in patients with relapsing forms of Multiple Sclerosis (MS) who are currently being treated with, but are considering discontinuing treatment with Tecfidera™.

Key inclusion Criteria:

• Diagnosis of relapsing form of MS
• Have declared a desire/plan to discontinue treatment with Tecfidera due to tolerability issues and/or lack of efficacy
• Expanded Disability Status Scale (EDSS) score 0 to 5.0 inclusive
• Other protocol defined inclusion criteria could apply

Key exclusion Criteria:

• Pregnant or lactating
• Significant renal or hepatic impairment or other significant disease that would compromise adherence and completion of the trial
• Other protocol defined exclusion criteria could apply